Publications
a) Peer-reviewed articles and books
• Kendre G, Marhenke S, Lorz G, Kühnel F, Woller N, Reineke-Plaaß T, Poth T, Becker D, Marquardt JU, Wirtz RM, Bonin M, Saborowski M, Vogel A*, Saborowski A* (2021). The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma. Hepatology. doi: 10.1002/hep.31799. *equal contribution.
• Ostroumov D, Duong S, Wingerath J, Woller N, Manns MP, Timrott K, Kleine M, Ramackers W, Roessler S, Nahnsen S, Czemmel S, Dittrich-Breiholz O, Eggert T, Kühnel F, Wirth TC (2020) Transcriptome profiling identifies TIGIT as a marker of T cell exhaustion in liver cancer. Hepatology. doi: 10.1002/hep.31466.
• Mishra A, Emamgholi F, Erlangga Z, Hartleben B, Unger K, Wolff K, Teichmann U, Kessel M, Woller N, Kühnel F, Dow LE, Manns MP, Vogel A, Lowe SW, Saborowski A, Saborowski M (2020) Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing. Carcinogenesis 41:334-344.
• Niemann J, Woller N, Brooks J, Fleischmann-Mundt B, Martin NT, Kloos A, Knocke S, Ernst AM, Manns MP, Kubicka S, Wirth TC, Gerardy-Schahn R, Kühnel F (2019) Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. Nat Commun 10:3236.
• Erlangga Z, Wolff K, Poth T, Peltzer A, Nahnsen S, Spielberg S, Timrott K, Woller N, Kühnel F, Manns MP, Saborowski A, Vogel A, Saborowski M (2019) Potent antitumor activity of liposomal irinotecan in an organoid- and CRISPR-Cas9-based murine model of gallbladder cancer. Cancers 11:1904.
• Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Demir IE, Armbrecht N, Ceyhan GO, Manns MP, Wirth TC, Kubicka S, Bernhardt G, Smyth MJ, Calvisi DF, Gürlevik E, Kühnel F (2018) Perioperative, spatiotemporally coordinated activation of T and NK cells prevents recurrence of pancreatic cancer. Cancer Res 78:475-488.
b) Other publications, both peer-reviewed and non-peer-reviewed
• Niemann J, Kühnel F (2020) Tumor targeting of oncolytic adenoviruses using bispecific adapter proteins. Methods Mol Biol 2058:31-49.
• Peter M, Kühnel F (2020) Oncolytic adenovirus in cancer immunotherapy. Cancers 12:3354
• Martin NT, Wrede C, Niemann J, Brooks J, Schwarzer D, Kühnel F*, Gerardy-Schahn R* (2018) Targeting polysialic acid-abundant cancers using oncolytic adenoviruses with fibers fused to active bacteriophage borne endosialidase. Biomaterials 158:86-94, *equal contribution.
• Wirth TC, Kühnel F (2017) Neoantigen targeting-dawn of a new era in cancer immunotherapy? Front Immunol 8:1848.
• Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM (2017) Virotherapy research in Germany: from engineering to translation. Hum Gene Ther 28:800-819.